GlassScriptPhysician profile
Latoya Beard
NPI 1316354673
$4,483.37
in general payments reported to CMS, 2019-2025
22 companies · $1,949 in 2025
The $1,949 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $21.71 · 2024: $2,512 · 2025: $1,949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,393 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,393.37 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,163.80 | 2024-2025 | Caplyta |
| Abbvie INC. | $427.08 | 2024-2025 | |
| Axsome Therapeutics, INC. | $348.84 | 2024-2025 | Auvelity, Sunosi |
| Ironshore Pharmaceuticals INC. | $232.77 | 2024 | |
| Jazz Pharmaceuticals INC. | $220.68 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $215.22 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $211.81 | 2024-2025 | Rexulti |
| Tris Pharma INC | $204.99 | 2024-2025 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $194.98 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $174.04 | 2024 | Adzenys Xr-Odt |
| Corium, LLC | $170.00 | 2024-2025 | Azstarys |
| Idorsia Pharmaceuticals US INC | $156.03 | 2024 | Quviviq |
| Neurocrine Biosciences, INC. | $133.51 | 2024-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $132.03 | 2024-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $121.83 | 2025 | Cobenfy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $82.53 | 2024-2025 | Uzedy, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $79.50 | 2024-2025 | Qelbree |
| Noven Therapeutics, LLC | $63.89 | 2024-2025 | Xelstrym, Secuado |
| Validus Pharmaceuticals LLC | $59.64 | 2025 | Raldesy, Equetro |
| Janssen Pharmaceuticals, INC | $54.81 | 2024-2025 | Spravato |
| Owp Pharmaceuticals, INC. | $19.50 | 2024 | Subvenite |
| Vanda Pharmaceuticals INC. | $15.89 | 2025 | Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latoya Beard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.